Medical Benefit vs. Pharmacy Benefit: Why the Difference Matters for Specialty Medications

The same drug can be reviewed by different decision-makers, against different criteria, through different channels, with different patient cost-sharing, depending on which benefit it processes under. Getting that determination right is the first step in medication access.

Two benefits, two administrative systems

Health coverage commonly separates drugs into two benefits; Medicare, for example, covers most provider-administered drugs under Part B and most self-administered drugs under Part D. The medical benefit covers services and the drugs a provider administers as part of them: infusions, injections, and other office- or facility-administered therapies. Those drugs are typically purchased by the practice, administered in the office, and billed to the health plan on a medical claim alongside the administration service. The pharmacy benefit covers drugs dispensed by a pharmacy for the patient to take or self-administer, adjudicated at the point of sale by a pharmacy benefit manager, or PBM, acting for the plan.

Many specialty medications sit on the boundary. An injectable biologic may be covered under the medical benefit when a clinician administers it and under the pharmacy benefit when the patient self-injects at home. Some plans allow either path; others require one, and some direct particular drugs to the pharmacy benefit or to a designated specialty pharmacy even when the drug will be administered in the office. The path is set by the plan and the product, and it can differ between two patients with the same diagnosis and the same prescription.

Who decides, and against what criteria

Under the medical benefit, the reviewer is the health plan or a utilization-management vendor it delegates to. The criteria come from the plan’s medical policy: diagnosis, clinical findings, prior treatments, dose and frequency, and increasingly the site of care. Under the pharmacy benefit, the reviewer is usually the PBM, applying its own clinical criteria for the drug, which also cover diagnosis, prior treatments, and dosing, together with formulary placement, preferred and non-preferred products, step-therapy requirements, and quantity limits. A drug can be approved under one benefit and denied under the other because the two reviewers are applying different rules.

How the authorization process differs

A medical-benefit authorization is requested from the plan or its vendor, usually through a portal, by fax, or by telephone, using procedure and drug codes, a diagnosis, and supporting documentation from the record. A pharmacy-benefit authorization is requested from the PBM, often through an electronic prior authorization process, and it is framed around the drug and the PBM’s criteria for it: the product, the strength and quantity, the diagnosis and clinical findings the criteria call for, the formulary alternatives the patient has tried, and, for an exception request, the reason a preferred product is not appropriate. Renewal cycles, appeal routes, and the forms of exception available also differ between the two.

Where the drug comes from

Under the medical benefit, the provider traditionally purchases the drug, stores it, administers it, and bills the payer for both the drug and its administration, the arrangement known as buy and bill. Under the pharmacy benefit, the drug is dispensed by a pharmacy, and for specialty products that is frequently a specialty pharmacy the plan designates. Some insurers instead require a third-party specialty pharmacy to dispense the drug and send it to the hospital or physician office for administration, a practice known as white bagging, or to dispense it directly to the patient, who brings it to the provider for administration, known as brown bagging. A number of states have enacted laws restricting payer-mandated white bagging. Each arrangement changes who orders the drug, who is paid for it, how it is tracked, and what happens when a dose is missed or a shipment is late.

What the patient pays

Cost-sharing follows the benefit. A drug under the medical benefit is usually subject to the plan’s deductible and coinsurance for medical services. A drug under the pharmacy benefit is subject to the formulary tier copay or coinsurance, and to a deductible where the plan applies one to pharmacy claims, whether a separate pharmacy deductible or a combined medical and pharmacy deductible. Financial assistance also varies by benefit and by program. Manufacturer copay programs, manufacturer patient-assistance programs, and independent foundation assistance each have their own eligibility rules and enrollment steps, and how assistance is applied depends on the program and on the benefit the drug processes under. For plans subject to the federal annual limitation on cost sharing, and to the extent permitted by applicable state and federal rules, an issuer may choose not to count direct manufacturer assistance toward the patient’s annual out-of-pocket limit; plans that make that choice are commonly described as operating copay-accumulator arrangements, which affect how long the assistance lasts. Separate rules may affect whether manufacturer assistance is credited toward a deductible, including specific requirements for high-deductible health plans. Other coverage types follow their own rules. A benefits investigation should establish which programs apply and how each is applied before the first fill or the first infusion.

Where practices get caught

• Requesting authorization under the wrong benefit, then discovering the error when the claim or the fill is rejected
• Obtaining a medical-benefit authorization for a drug the plan has moved to the pharmacy benefit, or to a mandated specialty pharmacy
• Missing a site-of-care requirement that limits where an infusion may be administered, such as a policy that steers a drug away from a hospital outpatient department to an office, an infusion center, or home infusion
• Tracking renewals on one cycle when the two benefits renew on different schedules
• Enrolling a patient in a copay program that does not apply to the benefit the drug actually processes under
• Losing visibility once the order leaves the practice for a specialty pharmacy, hub, or assistance program

What a disciplined workflow looks like

Benefit determination should be a discrete, documented step for every specialty medication, performed before any authorization is requested: confirm which benefit the plan applies to this product for this patient, identify the reviewer and the submission channel, and record the answer. From there the workflow branches, and each branch has its own checklist: authorization or exception, dispensing or purchasing route, assistance enrollment, and renewal date. The status of every party involved, the payer or PBM, the hub, the specialty pharmacy, and the practice, should be tracked through the administrative access process until the medication is available and treatment can proceed.

Ellery Health Partners performs that benefit determination and manages the administrative workflows under both benefit paths, with the practice’s clinicians retaining every prescribing and clinical decision.

Related services

• Medication Access & Pharmacy Benefits
• Prior Authorization
• Eligibility, Benefits & Financial Clearance
• Denials & Appeals

Sources

• Medicare.gov, Prescription drugs (outpatient). Part B generally covers drugs a provider administers in an office or hospital outpatient setting; Part D covers drugs obtained through a pharmacy, including self-administered drugs.
• CMS, Part B Drugs. Separately payable Part B drugs are billed by the provider and paid at a payment limit derived from the manufacturer’s reported sales price (ASP), the basis of the buy-and-bill model.
• Medicare.gov, Medicare drug plan rules. Pharmacy plans apply prior authorization, step therapy, and quantity limits, and exceptions may be requested with a supporting statement from the prescriber.
• HHS, Notice of Benefit and Payment Parameters for 2021, 85 FR 29164 (May 14, 2020). To the extent consistent with state law, amounts paid through direct manufacturer support may be, but are not required to be, counted toward the annual limitation on cost sharing, which is the regulatory basis of copay-accumulator arrangements for plans subject to that limit.
• IRS, Information Letter 2021-0014 (April 16, 2021). For a high-deductible health plan that permits health savings account contributions, the minimum annual deductible may only be satisfied by actual medical expenses the covered individual incurred; a manufacturer discount, or a rebate or coupon with the same effect, reduces the amount credited toward that deductible (citing Notice 2004-50, Q&A-9).
• HealthCare.gov glossary, Preauthorization. Preauthorization is a plan’s decision that a service, treatment, drug, or equipment is medically necessary, and is not a promise the plan will cover the cost.
• American Hospital Association, Health Insurer Specialty Pharmacy Policies Threaten Patient Quality of Care (2021). Defines buy and bill (the provider purchases, stores, and administers the drug and is reimbursed for the drug and its administration), white bagging (a third-party specialty pharmacy dispenses the drug and sends it to the hospital or physician office), and brown bagging (the specialty pharmacy dispenses directly to the patient, who brings it in for administration), and reports that a number of large private insurers have adopted such policies.
• Association for Clinical Oncology (ASCO), State of Play: White Bagging (December 2023). Describes payer-mandated white bagging, in which payers require physicians to obtain drugs from payer-owned or affiliated specialty pharmacies, and lists states that have enacted laws prohibiting or restricting the practice.

Sources are cited for the substantive factual statements above. Payer-specific rules vary by plan, product, contract, and state.

Last updated September 2026. Educational reference, not legal or clinical advice.